(S (PP (IN With) (NP (NP (DT the) (NN advent)) (PP (IN of) (NP (NP (JJ deep) (NN generative) (NNS models)) (PP (IN in) (NP (JJ computational) (NN chemistry))))))) (, ,) (NP (NP (ADJP (FW in) (FW silico)) (JJ anticancer) (NN drug)) (NP (NN design))) (VP (VBZ has) (VP (VBN undergone) (NP (DT an) (JJ unprecedented) (NN transformation)))) (. .))
(S (SBAR (IN While) (S (NP (ADJP (NN state) (HYPH -) (IN of) (HYPH -) (DT the) (HYPH -) (NN art)) (NML (JJ deep) (NN learning)) (NNS approaches)) (VP (VBP have) (VP (VBN shown) (NP (NP (JJ potential)) (PP (IN in) (NP (NP (VBG generating) (NNS compounds)) (PP (IN with) (NP (VBN desired) (NN chemical) (NNS properties)))))))))) (, ,) (NP (PRP they)) (VP (VBP disregard) (NP (NP (DT the) (JJ genetic) (NN profile)) (CC and) (NP (NP (NNS properties)) (PP (IN of) (NP (DT the) (NN target) (NN disease)))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP introduce) (S (NP (DT the) (JJ first) (JJ generative) (NN model)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG tailoring) (NP (JJ anticancer) (NNS compounds)) (PP (IN for) (NP (DT a) (JJ specific) (JJ biomolecular) (NN profile))))))))) (. .))
(S (S (VP (VBG Using) (NP (DT a) (NN RL) (NN framework)))) (, ,) (NP (NP (DT the) (JJ transcriptomic) (NNS profiles)) (PP (IN of) (NP (NN cancer) (NNS cells)))) (VP (VBP are) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN context)) (PP (IN for) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NN candidate) (NNS molecules))))))))) (. .))
(S (S (NP (PRP$ Our) (NN molecule) (NN generator)) (VP (VBZ combines) (NP (NP (CD two)) (FRAG (ADVP (RB separately)) (NP (NP (VBN pretrained) (JJ variational) (NNS autoencoders)) (-LRB- -LRB-) (NP (NNS VAEs)) (-RRB- -RRB-)))))) (, -) (NP (DT the) (JJ first) (NNP VAE)) (VP (VBZ encodes) (NP (JJ transcriptomic) (NNS profiles)) (PP (IN into) (NP (NP (DT a) (JJ smooth) (, ,) (JJ latent) (NN space)) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBZ is) (VP (VBN used) (S (VP (TO to) (VP (VB condition) (NP (DT a) (JJ second) (NN VAE)) (S (VP (TO to) (VP (VB generate) (NP (JJ novel) (JJ molecular) (NNS structures)) (PP (IN on) (NP (DT the) (VBN given) (JJ transcriptomic) (NN profile)))))))))))))))) (. .))
(S (NP (DT The) (JJ generative) (NN process)) (VP (VBZ is) (VP (VBN optimized) (PP (IN through) (NP (NP (NNP PaccMann)) (, ,) (NP (DT a) (ADJP (RB previously) (VBN developed)) (NML (NN drug) (NN sensitivity)) (NN prediction) (NN model)))) (S (VP (TO to) (VP (VB obtain) (NP (NP (JJ effective) (JJ anticancer) (NNS compounds)) (PP (IN for) (NP (DT the) (VBN given) (NN context))))))) (PRN (-LRB- -LRB-) (ADVP (FW i.e.)) (, ,) (NP (JJ transcriptomic) (NN profile)) (-RRB- -RRB-)))) (. .))
(S (NP (PRP We)) (VP (VBP demonstrate) (SBAR (WHADVP (WRB how)) (S (NP (DT the) (NN molecule) (NN generation)) (VP (MD can) (VP (VB be) (VP (VBN biased) (PP (IN towards) (NP (NNS compounds))) (PP (IN with) (NP (NP (JJ high) (VBN predicted) (JJ inhibitory) (NN effect)) (PP (IN against) (NP (NP (JJ individual) (NN cell) (NNS lines)) (CC or) (NP (JJ specific) (NN cancer) (NNS sites)))))))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBP verify) (NP (PRP$ our) (NN approach)) (PP (IN by) (S (VP (VBG investigating) (NP (NP (NN candidate) (NNS drugs)) (VP (VBN generated) (PP (IN against) (NP (JJ specific) (NN cancer) (NNS types))))))))) (CC and) (VP (VB find) (NP (DT the) (JJS highest) (JJ structural) (NN similarity)) (PP (IN to) (NP (VBG existing) (NNS compounds)))) (PP (IN with) (NP (NP (VBN known) (NN efficacy)) (PP (IN against) (NP (DT these) (NN cancer) (NNS types)))))) (. .))
(S (NP (PRP We)) (VP (VBP envision) (NP (PRP$ our) (NN approach)) (S (VP (TO to) (VP (VB transform) (NP (ADJP (FW in) (FW silico)) (NP (JJ anticancer) (NN drug) (NN design))) (PP (IN by) (S (VP (VBG leveraging) (NP (NP (DT the) (JJ biomolecular) (NNS characteristics)) (PP (IN of) (NP (NP (DT the) (NN disease)) (PP (IN in) (NP (NN order)))))) (S (VP (TO to) (VP (VB increase) (NP (NN success) (NNS rates)) (PP (IN in) (NP (JJ lead) (NN compound) (NN discovery))))))))))))) (. .))
